India's tech education landscape is increasingly embracing interdisciplinary and industry-integrated learning to nurture a ...

A US-based biotech company has successfully sequenced the genetic codes of preserved plants, some of which date back more ...

The global sales of microbial identification are estimated to be worth USD 4.69 billion in 2025 and anticipated to reach a value of USD 10.31 billion by 2035. Sales are projected to rise at a CAGR of ...

Sukhmal Kumar Jain has ceased to be the Chairman. Life Insurance Corporation of India has increased its stake in Tata Steel to 7.851% from 5.836% between July 28, 2022, and April 30, 2025.

The launch comes amid a surge in demand for artificial skin, with the market projected to grow from $3.1 billion in 2024 to $5.3 billion by 2032 Ayu Life Sciences, an India-based medical devices and ...

While this doesn’t make biotech investments completely unsustainable, it does shift the focus toward companies with more ... marketing and distribution in India. The company’s Afrezza business ...

It has a supply and distribution agreement with Biomm S.A. for commercialization in Brazil and with Cipla Ltd. for marketing and distribution in India ... is the pediatric market for children ...

After the allotment, the Government of India's shareholding in Vodafone stands at 48.99 per cent. Concord Biotech: The pharma company has received final approval from the USFDA to market its ...

Any future tariffs could disrupt this balance, impacting both the affordability of medicines in the U.S. and the profitability of Indian pharmaceutical companies. Medicamen Biotech has signed a ...

The company has a mission to serve patients in India, he stated ... am proud to welcome one of the world’s most renowned biotech companies to my city, setting up its first development facility ...

The portfolio will comprise 20-25 B2B startups spanning Pre-seed to Series A stages, addressing innovation gaps in areas such as pharmaceuticals, biotechnology, medical technology, specialty chemicals ...

Regardless of the bill’s fate, there appears to be a mandate for US biotech companies to shift their businesses away from China to other locations. India could be one of the destinations if it ...